

**Dr. Keith Manchester**

**Year of birth:** 1968

**Profession:** Managing Director and the Head of Life Sciences at QVT Financial LP

**Private residence:** New York, USA

Keith Manchester serves as a Managing Director and the Head of Life Sciences at QVT Financial LP, New York, an investment firm, where he has been employed since 2005. He focuses on investments in both publicly traded and privately owned life sciences companies. Dr. Manchester also serves as a director of Arbutus Biopharma Corporation, Myovant Sciences Ltd. and Roivant Sciences, Inc. Prior to joining QVT, Dr. Manchester was Vice President of Business Development from 2002 to 2004 and Director of Business Development from 2000 to 2002 at Applied Molecular Evolution, Inc., a biotechnology company. From 1999 to 2000, Dr. Manchester was an associate at Vestar Capital Partners, a private equity firm. From 1997 to 1999, Dr. Manchester was an investment banker in the healthcare group at Goldman, Sachs & Co. Dr. Manchester received his A.B. degree from Harvard College and his M.D. degree from Harvard Medical School.

**Further Board Memberships:**

Publicly listed companies:

- Arbutus Biopharma Corporation, Canada: Director since 2015
- Myovant Sciences Ltd., Bermuda: Director since 2016

Other companies/organizations:

- Roivant Sciences, Inc., Delaware, USA: Director since 2014, and Roivant Sciences Ltd., Bermuda: Director since 2014



**Ronald Scott**

**Year of birth:** 1955

**Profession:** Chief Executive Officer of Basilea Pharmaceutical International Ltd.

**Private residence:** Riehen, Switzerland

Ronald Scott has served Basilea Pharmaceutical International Ltd., Basel, Switzerland, as Chief Executive Officer since January 2013. He was Basilea's Chief Operating Officer from January through December 2012, and served as Basilea's Chief Financial Officer from the Company's founding in 2000 through January 2012 as well as ad interim Chief Financial Officer from February 2013 until November 2013. From 2004 to October 2011, Mr. Scott served on the Board of Directors and was a co-founding Board member in 2000. Prior to joining Basilea, Mr. Scott worked at Roche Holding AG (Roche) in management positions in Pharmaceutical Finance, Licensing, and the Roche Corporate Finance Mergers and Acquisitions group. Prior to joining Roche, Mr. Scott worked for Prudential Investment Corporation in the United States as Director in Prudential's Finance and International Business Development Units, managing divestitures and joint venture transactions. Mr. Scott has a bachelor's degree from Utah State University (USA) and a master's degree from Harvard University (USA).

**Other Board Memberships:** None



**Dr. Gerd Zettlmeissl**

**Year of birth: 1955**

**Profession: Self-employed consultant for immunotherapies**

**Private residence: Vienna, Austria**

Dr. Zettlmeissl has more than 25 years of scientific and leadership experience in the biopharmaceutical industry. He currently serves as representative of the Board of Directors of several non-profit organizations and biotech companies.

Until early 2015 he was chairman of GlycoVaxyn (Switzerland), an innovative vaccine company acquired by GlaxoSmithKline. He is the former CEO of the Austrian-based biotechnology company Intercell AG (now Valneva SE). While at Intercell AG from 2001 to 2011, he built the company from a private start-up venture to a publicly listed international organization with more than 400 employees. As CEO, he secured global regulatory approval for and led the launch of an improved Japanese Encephalitis vaccine, and oversaw efforts to build and advance a broad based development portfolio of vaccines. Prior to joining Intercell, Dr. Zettlmeissl was Managing Director of Chiron Behring GmbH and held senior management roles in biopharmaceutical R&D and Technical Operations at Chiron Corp. and Behringwerke AG. In 2010, he was named Vaccine Biotech CEO of the Year at the World Vaccine Congress. Dr. Zettlmeissl holds a doctoral degree in biochemistry of the University of Regensburg and did a post- doctoral fellowship at the Institut Pasteur Paris in virology.

#### **Further Board Memberships:**

Publicly listed companies:

- ASIT biotech, Brussels, Belgium: Member of the Supervisory Board since 2011; Chairman since March 2017

Other companies/organizations:

- MSD Wellcome Trust Hilleman Laboratories, New Delhi, India: Chairman of the Supervisory Board since 2013
- Themis Bioscience GmbH, Vienna, Austria: Chairman of the Supervisory Board since 2015
- Aeris, Rockville, MD, USA: Member of the Supervisory Board since 2011